



## Dr. rer. nat. Björn Moosmann

Rechtsmedizin · Dept. IV

### Kontakt

Dr. rer. nat. Björn Moosmann  
Rorschacherstrasse 95  
9007 St. Gallen

T +41 71 494 2163  
Bjoern.Moosmann@kssg.ch

### Orcid

0000-0003-1757-6359

### Bereiche

Rechtsmedizin

## Publikationen (12)

Bergerhoff M, Moosmann B. Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples. *Anal Chem* 2023

Volz M, Moosmann B. Development of a non-radioactive mass spectrometry-based binding assay at the  $\mu$ -opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles. *Anal Chim Acta* 2022; 1219:339978.

Erdmann J, Moosmann B. Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam. *Drug Test Anal* 2021; 13:1686-1688.

Moosmann B. New psychoactive substances—Designer benzodiazepines. *WIREs Forensic Science* 2021; 3:1416-1439.

Kissling S, Blum S, Beyer J, Moosmann B, Hausmann R (2020). Verzögerter Todeseintritt nach Einnahme von Natrium-Pentobarbital. Präsentiert bei: DGRM Jahrestagung, Luzern

Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). *Drug Test Anal* 2019; 11:541-549.

Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. *Forensic Toxicol* 2018; 37:186-196.

Mogler L, Franz F, Wilde M, Huppertz L, Halter S, Angerer V, Moosmann B, Auwärter V. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. *Drug Test Anal* 2018; 10:1417-1429.

Moosmann B, Auwärter V. Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: *New Psychoactive Substances*. Springer, Cham, 2018. S. 383-410.

Mogler L, Moosmann B, Kassiou M, Banister S, Longworth M, Weinfurtner G, Angerer V, Rentsch D, Franz F, Auwärter V. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. *Drug Test Anal* 2017; 10:196-205.

Huppertz L, Moosmann B, Auwärter V. Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. *Drug Test Anal* 2017; 10:206-211.

Moosmann B. Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. In: *Handbuch Psychoaktive Substanzen*. Heidelberg: Springer, 2016. S. 389-409.

## Projekte (1)

### **Novel screening assay for novel psychoactive substances**

*Grundlagenforschung - 01.05.2024 - 30.04.2025*

*Geplant*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)